Identification of Low Allele Frequency Mosaic Mutations in Alzheimer Disease by Frigerio, CS et al.
Chapter 17: Somatic mutations in AD 
 1 
Chapter 17 
 
Identification of low allele frequency mosaic mutations in Alzheimer Disease 
 
Carlo Sala Frigerio 1,2,*, Mark Fiers 1,2, Thierry Voet 3,4, and Bart De Strooper 1,2,5,* 
 
1 VIB Center for Brain & Disease Research, Leuven, Belgium 
2 Center for Human Genetics, Universitaire ziekenhuizen and LIND, KU Leuven, Leuven, 
Belgium 
3 Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium 
4 Wellcome Trust Sanger Institute, Hinxton, UK 
5 Dementia Research Institute (DRI-UK), University College London, Queen Square, WC1N 
3BG London, UK 
 
 
 
* Corresponding authors contact information: 
Bart De Strooper 
Email: bart.destrooper@cme.vib-kuleuven.be 
VIB Center for Brain & Disease Research KU Leuven O&N 4 
Herestraat 49, bus 602 
3000 Leuven 
Belgium 
 
Carlo Sala Frigerio 
Email: carlo.salafrigerio@cme.vib-kuleuven.be 
Chapter 17: Somatic mutations in AD 
 2 
VIB Center for Brain & Disease Research KU Leuven O&N 4 
Herestraat 49, bus 602 
3000 Leuven 
Belgium 
 
 
 
 
Running head: Somatic mutations in AD 
 
  
Chapter 17: Somatic mutations in AD 
 3 
i. Summary 
 
Germline mutations of APP, PSEN1 and PSEN2 genes cause autosomal dominant Alzheimer 
disease (AD). Somatic variants of the same genes may underlie pathogenesis in sporadic AD, 
which is the most prevalent form of the disease. Importantly, such somatic variants may be 
present at very low allelic frequency, confined to the brain, and are thus very difficult or 
impossible to detect in blood-derived DNA. Ever-refined methodologies to identify mutations 
present in a fraction of the DNA of the original tissue are rapidly transforming our 
understanding of DNA mutation and their role in complex pathologies such as tumours. These 
methods stand poised to test to what extend somatic variants may play a role in AD and other 
neurodegenerative diseases. 
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1. Introduction 
 
Many neurodegenerative diseases, such as Alzheimer disease (AD) and Parkinson disease (PD), 
have an important genetic component, and may present as familial or sporadic forms. In AD, 
familial forms (FAD) show dominant autosomal inheritance and are associated with point 
mutations in three genes (APP, PSEN1 and PSEN2) [1], although cases of duplication of the 
APP locus are also known [2]. The causes of sporadic AD (SAD) have not yet been identified, 
however the clinical, histopathological and biochemical similarities between SAD and FAD 
cases suggest a common pathological cascade.  
Given the enormous genomic heterogeneity found in cells comprising the human brain [3–7], 
it is fair to hypothesize that during brain organogenesis some individuals may acquire somatic 
mutations in genes known to be causative in FAD forms. These individuals would then have 
patches of brain tissue bearing pathogenic mutations, which could start the same pathological 
cascade of events as seen in FAD patients, causing sporadic AD. Indeed, patches of neurons 
bearing somatic mutations of FAD genes would produce Aβ or tau aggregates, which could 
then spread in the brain parenchyma seeding further aggregation of amyloid or tau, respectively, 
in a process known as template-seeded aggregation [8, 9] (Figure 1). 
Single nucleotide variants (SNVs) are the most abundant class of mutations responsible for 
genomic variation between humans at a population level [10], and hence a main cause of 
cellular genomic heterogeneity within an individual. Indeed, it is estimated that per cell division 
approximately 10-10 errors per base pair accumulate [11], suggesting that a large majority of 
cells within a body may be genetically dissimilar. Whole genome sequencing of single human 
neurons suggests the presence of approximately 1500 somatically acquired SNVs per neuron 
[3]. Interestingly, transcriptionally active genes were enriched for somatic SNVs and the latter 
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were often private to single neurons, indicating that also mechanisms other than DNA 
replication are causal for somatic DNA mutations [3] (Figure 1). 
Analysis of somatic mutations is a rapidly evolving field, that has seen a fast improvement in 
recent years thanks to the development of high throughput / next generation sequencing (NGS) 
and more refined data analysis algorithms. There is not yet a unique gold standard method for 
somatic mutation detection, moreover different methods are required for investigating fine-
grain mosaicism (due to private somatic mutations present in very small numbers of cells) when 
compared to coarse-grain mosaicism (due to somatic variants present in a sizeable percentage 
of brain cells) (Figure 1). In this chapter we will present methodologies available for 
investigating somatic variants, with a particular focus on those we have employed in our 
laboratory. Of importance, the same methodologies could be applied to the study of other 
neurodegenerative diseases for which a similar somatic mutation-based hypothesis can be 
envisaged, e.g. Parkinson disease (by targeting SNCA, LRRK2, VPS35 and possibly PINK1, DJ-
1 and PARK2 genes) and prion diseases such as Creutzfeldt-Jakob (by targeting the PRNP gene) 
[12]. 
 
2. Methodologies 
 
The search for somatic variants present in a sizeable fraction of brain cells can be performed by 
analysing bulk DNA extracted from a frozen post-mortem brain tissue sample. The technical 
challenge of this approach lies in the fact that when only a few clonal cells contribute the signal 
for the mutant allele, thousands or millions of other cells will deliver a wild type signal. Classic 
Sanger DNA-sequencing is not very well suited to detect somatic mutations with low allele 
frequency, having a sensitivity threshold that approximates 20% mutant allele frequency (ALT) 
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[13, 14]. The development of NGS technologies has allowed more profound analysis of bulk 
DNA samples: by independently sequencing hundreds to thousands of alleles from the starting 
DNA sample, wild type and mutant signals at a particular genomic locus can be efficiently 
detected thus allowing to reach sensitivities of 5% ALT and lower. Although powerful, NGS 
sample preparation often involves several steps of PCR amplification of the original DNA, 
leading to polymerase errors. Moreover, the sequence-by-synthesis chemistry of Illumina (a 
widely used sequencing technology today) is also error-prone. Effectively, all in vitro 
polymerase errors limit the sensitivity of detection of genuine low frequency mutations. To 
overcome such limitations of NGS, several methods for sample preparation and data analysis 
have been developed. 
To achieve the high sequencing depth that is required for the detection of somatic mutations 
with low ALT cost efficiently, it is recommended to focus the analysis only on specific target 
regions of the genome that are already suspected to be involved. In the case of AD, it makes 
sense to selectively sequence the APP, PSEN1 and PSEN2 genes, as these are the only genes 
known to cause FAD when mutated, foregoing the analysis of the rest of the genome/exome. 
This targeted approach can be attained with two different methodologies: 1) targeted 
enrichment or capture using a custom probeset on a genome sequencing library, or 2) target 
amplicon generation using a custom multiplexed PCR. Several vendors offer custom-designed 
sequence-enrichment and/or target-amplicon panels, e.g. Agilent SureSelect Target Enrichment 
system, Illumina Nextera Rapid Capture Custom Enrichment kit and TruSeq Custom Amplicon 
kit, Qiagen GeneRead DNAseq custom panels, Raindance ThuderStorm and ThunderBolt 
systems, and Roche NimbleGen’s SeqCap. It is recommended to test the sensitivity and 
accuracy of the targeting approach chosen at the beginning of a research project. This can be 
done by setting up a preliminary experiment analysing a series of “synthetic mosaic” samples, 
which can be obtained by serially diluting a bulk DNA sample containing known heterozygous 
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mutations in the region of interest with bulk wild type DNA. The expected allelic frequency of 
the “synthetic mosaic” variants can then be compared to the observed values and to the overall 
sequencing noise. This provides information about the lowest allelic frequency reliably 
detectable and about which parameters in sample preparation / data analysis would need 
optimization. 
The study of fine-grained mosaicism requires to sequence the DNA of single cells: by querying 
each cell on its own, the contribution of each cell to the overall genomic heterogeneity of the 
brain can be determined. In addition to the limitations inherent to NGS (see above), single cell 
DNA sequencing is confounded by the minute amounts of starting material (6.6 pg of DNA for 
a diploid cell) that has to be amplified prior to sequencing. Such whole-genome amplification 
(WGA) procedures can lead to false positives –e.g. due to DNA polymerase errors in early 
rounds of amplification – as well as to false negatives –e.g. due to locus or allelic dropout. 
Several WGA methods have been developed, the choice for a specific method is primarily 
guided on the desired classes of genetic variation to be detected genome wide [15, 16].  
 
2.1 Considerations on the tissue samples to be investigated 
 
Depending on the developmental timing of its appearance, a somatic mutation will be spread 
more or less throughout the body; while early events could lead to a mutation being present in 
a fraction of both blood and neuronal cells, it is possible to have brain-private somatic mutations 
if they appeared after gastrulation. Therefore, in order not to miss somatic mutations present 
only in the brain, we have analysed brain tissue samples from deceased AD patients instead of 
blood-derived DNA.  
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Somatic mutation analysis in neurodevelopmental diseases and cancer is facilitated by the fact 
that diseased tissue can be clearly identified thanks to specific histological features. DNA 
isolated from the diseased tissue will be enriched for the mutant signal, while parallel 
sequencing of healthy tissue provides a background reference to exclude germline and de-novo 
mutations and to control for sequencing errors. Unfortunately, in AD it is not possible to clearly 
discern a brain area which is more likely to harbour a somatic variant. Reports of a patterning 
in the perceived spread of tau aggregates suggests that the entorhinal cortex could be one of the 
earlies areas affected [17], however the mechanistic implications of the “prionoid spread” of 
amyloid seeds suggests that any brain area could be the source of the first amyloid seeds. 
Therefore, the search for somatic mutations in sporadic AD should be directed towards several 
different brain areas. 
 
2.2 Bulk DNA sequencing: sequence-enrichment approach 
 
We have previously employed a custom Roche NimbeGen SeqCap panel to enrich sequencing 
libraries for the loci of APP, PSEN1, PSEN2 and MAPT [18]. The MAPT gene was included in 
the analysis even though germline MAPT mutations do not cause AD for the reason that tau, 
the product of the MAPT gene, is a primary player in the biochemical pathological cascade of 
AD; in a somatic mutation scenario it can be thus hypothesized that somatic MAPT mutations 
could lead to AD in a “two-hit” mechanism [19]. A more conservative approach would be of 
course to only consider the three known FAD-causative genes (APP, PSEN1 and PSEN2). 
We chose to target the entire loci of our genes of interest, so that we could leverage the 
sequencing data to simultaneously analyse both somatic SNVs and CNVs, exploiting 
disturbances in B-allele fractions of germline heterozygous SNPs for the detection of subclonal 
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CNVs. Both types of somatic mutations could be relevant for the development of AD. We also 
included 10 kbp pad regions upstream and downstream of each locus to avoid drastic drops in 
sequencing coverage at both ends of the loci, which would otherwise complicate the analysis. 
The regions targeted were (based on the Human Genome release hg19): APP (chr21:27242859-
27553138), PSEN1 (chr14:73593141-73700399), PSEN2 (chr1:227048271-227093804) and 
MAPT (chr17:43961646-44115799). As the hg19 release also foresees an alternative assembly 
for chromosome 17, we also included the MAPT regions specific for the alternate assembly 
(chr17_ctg5_hap1:762280-895830). The actual probes were designed by NimbleGen according 
to our desired target areas, manufactured and shipped in solution. 
The experimental workflow begins with the isolation of high quality gDNA from tissue 
samples. To isolate bulk gDNA, frozen brain tissue is chopped with a scalpel and incubated 
overnight with Protease K at 50°C with mild agitation. RNA is then degraded during a 15 
minute incubation at 37°C with RNase A (Qiagen, Venlo, The Netherlands). DNA is isolated 
with phenol:choloroform:isoamyl alcohol, washed twice with choloroform:isoamyl alcohol and 
precipitated with 100% ethanol. The DNA pellet is further washed with 70% ethanol, dried and 
finally resuspended in Tris-EDTA buffer. Sample preparation must avoid excessive vortexing 
or heating, as this would fragment or denature gDNA and render subsequent steps impossible. 
The concentration of the DNA is determined with a QuBit fluorimeter (Life Technologies, 
Gent, Belgium), which specifically detects double-stranded DNA, and quality is determined 
with a NanoDrop spectrophotometer (NanoDrop, Wilmington, DE) to exclude residual 
contaminants. 
High quality gDNA is sheared with a Covaris sonicator (Covaris, Woodingdean Brighton, UK) 
to produce 300 bp fragments on average and indexed libraries are then prepared with the 
TrueSeq DNA kit from Illumina (Illumina, San Diego, CA). Individual libraries can then be 
pooled prior to sequence enrichment, the number of samples that can be pooled is function of 
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the total number of bases captured, the intended sequencing depth for every base and the 
sequence output of the instrument that will be used to analyse the samples. For this, the 
projected output of the instrument (according to the manufacturer) can be divided by the size 
of the target region and by the desired sequencing depth. We have obtained high sequencing 
depth (>2000X per position, on average) by pooling 10 samples enriched for a ~600 kb target 
region and sequencing with an Illumina HiSeq 2500 in rapid mode. Demultiplexing the 
sequencing data amongst the pooled samples is a critical step to avoid the wrong assignment of 
reads to a particular sample which may result in false signals. Sample-specific indices are 
preferably at least 3 nucleotides different, allowing maximum one mismatch in the index 
sequence during demultiplexing. After demultiplexing, sequencing data are usually encoded in 
FASTQ files. 
Sample-individual FASTQ files are aligned to the human reference genome using BWA [20] 
and converted to a BAM file format for downstream analysis [21]. Next, since indels can cause 
misalignment of the reads, the alignment should be refined by local realignment around indels 
using the GATK IndelRealigner tool [22], and base qualities are recalibrated using the GATK 
BaseRecalibrator tool [22] to correct systematic technical errors in base quality calling by the 
sequencing instrument. These steps of data pre-processing will yield a BAM file which can then 
be used to call variants. There is a great variety of variant calling algorithms (see Table) based 
on different statistical algorithms. We have efficiently used Samtools mPileup function [23] 
together with VarScan 2.0 [24] to generate a list of candidate somatic variants. A useful 
approach for variant calling involves the generation of a conservative list of candidate variants 
called by different algorithms. Indeed, each variant calling software may identify different sets 
of variants, due to the unique properties of each algorithm. Variants called by multiple 
algorithms may be considered as high confidence candidates. 
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Of importance, some somatic variant calling algorithms expect that a test sample is compared 
with a “matched normal” sample (e.g. a tumour sample compared to a healthy tissue sample) 
to efficiently rule out false positive calls and germline variants. In the case of AD tissue, it is 
not possible to perform such comparison, since, differently from tumour studies, it is not 
obvious which tissue should have a somatic mutation and which should be devoid of it. Hence, 
we performed variant calling on each sample on its own. 
Candidate variants are then annotated, i.e. information on the genomic region, presence in 
databases and potential functional consequences (synonymous, nonsynonymous, nonsense,…) 
is retrieved, finally yielding a VCF (variant call format) file. Various tools exist also for variant 
annotation, we have used SnpEff [25] and Annovar [26]. Further analysis of variants and 
sequencing data can be carried out efficiently using R (http://www.r-project.org/). Annotation 
of variants can be useful to prioritize a long list of candidate variants for further validation and 
is instrumental in gaining insight on the biological consequences of true somatic variants. 
It is important to notice that all the above-mentioned software is constantly updated, hence it is 
recommended to use the latest versions, to consistently use one version for the analysis of all 
samples in a project, and in any case to correctly report the version number of each software 
used. 
The bioinformatics analysis can be computationally intense, in particular the alignment step, 
the GATK-based steps, and the steps in R if dealing with a big target region or a high number 
of candidate variants. Analysis can be efficiently tackled by computing clusters or by the use 
of dedicated servers.  
 
2.3 Bulk DNA sequencing: targeted approach with tagged reads 
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Preparation of sequencing libraries involves several PCR steps, which introduce errors which 
may complicate somatic variant analysis. The main errors due to PCR are: 1) the incorporation 
of wrong nucleotides and 2) the skew in amplification of mutated alleles and wild type alleles 
(see Figure 2) which could result in false negative (in case the mutant allele is under-
represented) or false positive (in case a PCR error is over-represented) calls. The skewed 
amplification behaviour and the introduction of incorrect nucleotides are inherent to PCR and 
DNA polymerases [27, 28], however several smart workarounds have been developed to 
prevent and counter them. 
Two approaches (Duplex Sequencing [29] and UMI-TSCA [30]) share the general principle to 
add barcodes to the original DNA molecules in order to track the daughter molecules produced 
during PCR amplification. This allows 1) to correctly remove PCR duplicates (deduplication) 
by counting unique barcodes instead of raw reads, and 2) to generate consensus reads by pooling 
all reads sharing the same barcodes (Figure 2). 
In the Duplex Sequencing approach [29, 31], gDNA is sheared and fragments are ligated to 
duplex sequencing adapters, resulting in DNA fragments bearing 12-nucleotide long barcode 
sequences at both ends. Fragments barcoded at each end are PCR amplified and sequenced, 
then reads are grouped by the barcodes and consensus sequences are derived. This approach 
also allows to double-check a variant by identifying its presence in both families of sequencing 
reads that derive from the complementary Watson and Crick strands of the original gDNA 
molecule. However, this method still requires the development of a sequence enrichment panel 
to prepare a targeted sequencing library. 
An alternative approach [30] applies a modification of the TruSeq Custom Amplicon (TSCA) 
kit from Illumina to introduce a Unique Molecule Identifer (UMI) in place of the P5 sample 
index. The TSCA kit is a custom-designed panel of probes recognizing a list of user-defined 
genomic targets; for each target, two probes are designed, one upstream and one downstream. 
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After hybridization to the gDNA targets, the upstream probe is extended by a DNA polymerase 
onto the downstream probe, producing a copy of the original gDNA region. Next, a unique 
barcode is added to each copy and the product is PCR amplified to produce the sequencing 
library: during this step the barcodes are copied together with the genomic target, thus keeping 
the original labelling. This approach is more straightforward than the former, as it directly 
generates a targeted amplicon library, however it lacks the possibility of copying both strands 
of the original gDNA target. 
A third method, CirSeq [32], dispenses from using barcodes altogether: instead of PCR 
amplifying the intended target, the gDNA is sheared, fragments are circularized and using 
random primers and a high processivity DNA polymerase concatenated copies of the original 
template are made. The strength of the method lies in the fact that mutations are not propagated 
by PCR, as each new copy comes from the original DNA sequence. However, it also requires 
an extra step to select the regions of interest when dealing with a targeted approach, which 
would require additional PCR reactions. 
We have applied the UMI-modified TSCA approach to analyse somatic mutations in AD, our 
choice was based on the fact that this approach is the most straightforward for a targeted 
sequencing analysis, and built around a commercially available kit already aimed at the analysis 
of large genomes (such as the human genome). In order to maximize the sequencing coverage 
of areas of interest we targeted the exons of APP, PSEN1, PSEN2 and MAPT known to harbour 
pathogenic mutations. The TSCA panel was designed by Illumina, to accommodate 250 bp-
long amplicons, the total area covered is ~7 kb long thus allowing a very high coverage when 
sequencing 12 pooled samples on an Illumina MiSeq 2x300 sequencing run. 
To prepare sequencing libraries with the modified TSCA method, first the gDNA is denatured 
and slowly cooled in presence of the probeset, allowing specific annealing of the probes with 
their cognate sites on the gDNA. Next, a DNA polymerase extends the upstream probe and a 
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DNA ligase joins the newly synthesized copy of the gDNA to the downstream probe. The 
ligation-extension products are purified using a filter plate (provided with the kit, per 
manufacturer’s recommendations). Next, in place of the canonical direct PCR amplification of 
the extension-ligation products, we performed one cycle of PCR with the Illumina P7 primers 
(bearing a sample-specific index) and a modified P5 primer (P5’) which contains a random 12-
nucleotide sequence (which constitutes the UMI) in place of the second sample-specific index. 
Given the high number of possible UMIs (412=16,777,216), it is highly likely that each copy of 
a specific genomic target in the original sample will get a different UMI. Next, PCR products 
are purified with Ampure XP magnetic beads and a second round of PCR is carried out using 
the same sample-specific P7 primer as before and a P5’’ primer that anneals downstream of the 
UMI and carries the Illumina-specific P5 sequence handle for correct loading on an Illumina 
flowcell. The final PCR product is again purified using Ampure XP magnetic beads, quantified 
using the KAPA library quantification kit for Illumina libraries (Kapa Biosystems, Wilmington, 
MA), and equimolar sample-specific libraries are pooled. Since only the P7 sample index can 
be used to label different biological samples, the maximum amount of samples that can be 
pooled on a single sequencing run is 12, as Illumina provides only 12 different P7 indices, 
restricting high sample throughput. 
The Illumina MiSeq sample sheet (which instructs the sequencing instrument on the run 
parameters) has to be modified to account for a longer (12 nucleotides instead of 8) i5 index 
read (which covers the UMI). In order to keep the UMI tied to each specific R1 and R2 read 
pair (which cover the actual amplicon), we have appended the UMI sequence to the header of 
each R1 and R2 read. To analyse the data, we first aligned the reads to the reference genome 
using BWA-MEM, and performed local realignment around indels and base quality 
recalibration with the dedicated GATK software. 
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Next, UMIs are leveraged to correct for PCR artefacts and to generate consensus nucleotide 
calls at each position assessed. The overall approach is to group reads aligned to one genomic 
locus that share the same UMI (called “UMI family”). Subsequently, analysis can focus on a 
read-by-read basis or on a position-by-position basis. Following the latter approach, we have 
developed an algorithm (called Scotoplanes, Figure 3) which generates a pileup of the 
nucleotides aligned at each position of our target region, while taking the UMI into account. 
Deduplication of reads nucleotides with the same UMI depends on the level of UMI duplication 
and whether or not all the reads with the same UMI support the same nucleotide: 1) a UMI 
appears only once: the associated nucleotide is counted (e.g. UMI1, Figure 3); 2) a UMI is 
observed more than once, but all instances support the same nucleotide: the nucleotide is 
retained but counted only once (e.g. UMI2, Figure 3); 3) a UMI is observed more than once, 
and associates with a number of different nucleotides: the most abundantly present nucleotide 
is retained (and counted once), but only if it is at least four times more abundant than the second 
most frequent nucleotide associated with the same UMI at that position (e.g. UMI3, Figure 3). 
After such position-by-position UMI deconvolution, allele frequencies are calculated at each 
position, and major and minor alleles are called. Candidate variants can then be annotated using 
SnpEff and Annovar as seen above to prioritize variants for further validation. 
 
2.4 Single cell DNA sequencing 
 
Single cell DNA sequencing has the capacity to detect somatic variants down to the biological 
unit of organs. Although powerful, the method is still technically highly challenging, which has 
to be taken into account when designing a project [16]. In particular, a cell’s gDNA has to be 
amplified to obtain enough material for sequencing analysis; and methods for WGA are still in 
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need of optimization to improve uniformity of coverage – whereby unevenness in amplification 
can lead to locus or allelic drop outs and thus false negative SNVs as well as false positive 
CNVs – and to mitigate the introduction of polymerase errors which produce false positive 
SNVs [16]. 
As it is difficult to isolate intact single cells from a complex tissue such as the human brain, it 
is preferable to isolate single nuclei instead. For nuclear isolation, tissue samples are 
homogenized in the presence of very low levels of detergent in order to avoid compromising 
the nuclear envelope. Nuclei can be recovered by centrifugation on an Optiprep density 
gradient. The nuclei are then labelled with a DNA stain (e.g. DAPI or DRAQ5) and can be 
additionally marked for cell-type specific nuclear antigens. For example, to specifically recover 
neuronal nuclei one can use a fluorescently-conjugated antibody for the neuronal-specific 
splicing regulator Rbfox3 (NeuN). Fluorescently labelled nuclei can subsequently be single-
sorted into 96 well plates containing lysis buffer using fluorescent activated cell sorting (FACS) 
platforms. Following isolation, for the purpose of SNV analysis the gDNA of the cell is 
preferably amplified by isothermal amplification using random primers and the Φ29 
polymerase, a DNA polymerase with high processivity and low error rates [15, 33]. The 
resulting multiple displacement amplification (MDA) product can be converted in a sequencing 
library using conventional methods, or can be used in conjunction with a sequence-enrichment 
approach. As for bulk DNA approaches, it is best to include a sequence-enrichment step to 
focus on genomic regions which, if mutated, could drive AD pathogenesis. 
Although variant calling algorithms developed for bulk DNA have also been used for calling 
variants in single cell DNA sequencing data, this latter kind of data has peculiar aspects which 
warrants the use of bespoke algorithms. Specifically, the technical artefacts introduced during 
WGA need to be taken into account, to prevent calling false variants. Due to the error rate of 
WGA polymerases –e.g. the per-cycle per-base error rate of MDA has been estimated to 
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approximate 3.2 x 10-6 [34] – it is currently impossible to call SNVs that are private to a cell 
with absolute confidence [15]. Instead, the candidate SNV has to be reported by at least a few 
cells to increase reliability. Algorithms specifically designed for analysing SNVs in single cell 
DNA sequencing data, as Monovar [35] and Single Cell Genotyper [36], are emerging. 
Single cell DNA sequencing has been used widely to study tumour evolution, and recently it 
has been used for the identification of somatic mutational signatures in the human brain [3]. A 
possible future application to investigate somatic genetic variation underlying the cause of AD 
would be to couple single nucleus sorting and DNA library preparation with a sequence 
enrichment panel targeted for the APP, PSEN1 and PSEN2 loci. Alternatively, a direct amplicon 
based assay targeting the most pathogenic mutant sites for AD may be directly applied on single 
cell DNA at scale without upfront WGA [37]. Although single-cell sequencing allows SNV 
analysis at relatively low coverage, many different cells may need be to be pooled and 
sequenced for the discovery of low frequency somatic SNVs in the diseased tissue.  
 
3. Confirmation of candidate somatic variants 
 
Although bioinformatics analysis of sequencing data is based on continuously improving 
algorithms, the stochastic nature of errors introduced at any step of sample preparation and 
sequencing means that the analysis can at best give a list of candidate variants with differing 
degrees of confidence. Confirmation of called somatic variants by an alternative approach 
remains therefore important to validate the results and to develop increasingly reliable somatic 
variant callers. There are several ways to confirm candidate variants, depending on the approach 
used at first pass (bulk tissue or single cell analyses), the allelic frequency of the candidate 
variant and the number of candidates to be tested (for budgeting reasons). 
Chapter 17: Somatic mutations in AD 
 18 
 
3.1 Sanger sequencing 
 
The resolution of Sanger sequencing for detecting somatic variants is limited to variants with 
an allelic frequency of 20% or more [13, 14]. In this procedure, the candidate mutant locus is 
amplified from bulk DNA with specific PCR primers and then directly sequenced. However, it 
requires that the sequencing runs have very low levels of noise to be able to reliably identify 
the somatic variant. Parameters that have to be carefully controlled are in particular the clean-
up and resuspension of the sample after the PCR with fluorescent dideoxy nucleotides. In 
practice, it is more efficient to use alternative methods even for high allele frequency somatic 
variants. 
 
3.2 TA-subcloning and Sanger sequencing 
 
The principle of this approach is to exploit bacteria to partition the bulk DNA signal, so that 
Sanger sequencing can be efficiently used to validate a candidate somatic variant. 
The candidate mutation is amplified from the original bulk gDNA sample using a pair of 
specific PCR primers. The PCR amplicons are then cloned into a plasmid vector, ideally one 
which allows quick and efficient subcloning without the need for restriction digest of the 
amplicon such as those provided by the TOPO TA cloning kit from ThermoFisher 
(ThermoFisher, Waltham, Massachusetts). After bacterial transformation and plating, single 
independent colonies are isolated and sequenced. Each colony will bear only one allele, hence 
Sanger sequencing will yield a yes/no answer for the presence of the candidate mutation. By 
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counting the ratio of mutant colonies, we can infer the allelic frequency of the target mutation 
in the original DNA sample. 
This approach works best with mutations having a relatively high allelic frequency, to avoid 
having to sequence many colonies, but could in theory be up-scaled to detect low frequency 
variants. 
 
3.3 Digital droplet PCR 
 
Following the same principle of partitioning the original bulk gDNA signal, digital droplet PCR 
(ddPCR) allows to achieve very good sensitivity, down to 0.1% ALT or lower (Figure 4) [38]. 
In a ddPCR assay, a PCR reaction is mixed with oil in a microfluidics chip, leading to 
emulsification of the PCR reaction into thousands of nanoliter droplets containing either zero, 
one or more than one template DNA molecules. After completion of the PCR reaction, droplets 
are read one by one, measuring the presence of fluorescently labelled allele-specific probes. 
Statistical analysis of the count data, based on Poisson statistics, allows calculating confidence 
levels for the allelic frequency determined for each sample. The extremely high partition of the 
template DNA and the discrete nature of droplet counting allows to detect very low levels of 
mutant allele molecules.  
For each candidate variant a specific PCR primer set is designed together with two hydrolysis 
probes (e.g. Taqman probes), one recognizing the wild type allele and one recognizing the 
mutant allele, labelled with fluorophores with different spectral wavelengths (e.g. FAM and 
HEX). The use of two differentially labelled probes allows the simultaneous detection of the 
two alleles in the same reaction, thus offering a better quantification than running mutant and 
wild type assays in different tubes. For each newly developed assay, several parameters need 
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to be optimized, including correct annealing temperature, starting gDNA quantity and the 
numbers of wells/droplets required. 
Each assay should be run with appropriate negative and positive control samples. As negative 
control samples, assays should be run without template gDNA to assess the levels of inherent 
background fluorescence of the probes, and should be run with gDNA devoid of the target 
somatic variant (wild type control) to assess the signal coming from non-specific PCR products. 
As positive controls, a dilution series of a construct containing the target somatic variant spiked 
to wild type DNA could be analysed. For this purpose, a gBLOCK synthetic double stranded 
DNA molecule mimicking the genomic region containing the somatic variant can be ordered 
from IDT (Integrated DNA Technologies, Leuven, Belgium). Such dilution series will allow to 
readily assess the sensitivity of the assay against the noise signal derived from the analysis of 
pure wild type samples. BioRad (Hercules, CA) provides a complete workflow for ddPCR 
analysis. Assays can be designed using their online software (https://www.bio-rad.com/digital-
assays/#/assays-create/mutation). The BioRad QX200 Droplet Digital PCR system foresees an 
instrument for the preparation of the emulsion PCR reaction and a droplet counter. Moreover, 
BioRad provides a software (QuantaSoft) to analyse droplet counts (Figure 4). 
 
3.4 Resequencing of candidate variants 
 
Another approach to validate candidate variants is to re-sequence at very high depth target 
amplicons: as most PCR and sequencing errors are random, it would be unlikely to retrieve a 
false positive variant in two separate sample preparations and sequencing runs. 
Deep amplicon sequencing is a viable validation option for candidates identified by a sequence-
enrichment approach. Primer sets are designed to amplify each target candidate, and each PCR 
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product is labelled with a sample-specific index to allow for pooling. Amplicons can then be 
sequenced at very high coverage (>100,000X) on an Illumina MiSeq. 
For candidates identified in an amplicon-based approach a more relevant re-sequencing 
approach would entail change of sequencing chemistry altogether. Pacific Biosciences (PacBio) 
sequencing offers a good alternative to Illumina sequencing for this kind of validation, as the 
sequencing chemistry, and therefore the error pattern, are radically different between the two. 
For PacBio sequencing, after preparing indexed amplicons, library preparation foresees the 
ligation of bubble adaptors on both ends of each DNA molecule, enabling recursively 
sequencing of the Watson and Crick DNA strands of that molecule on an RSII or Sequel 
platform (Pacific Biosciences, Menlo Park, CA). Following sequencing, all subreads from a 
DNA molecule are piled and a consensus sequence is derived. As PacBio polymerase errors are 
stochastic, the consensus sequence generation is able to correct most sequencing errors, thus 
providing a high confidence validation. 
 
4. Conclusions 
 
Somatic variant analysis is a rapidly developing field, with continuously improved sample 
preparation and sequencing methodologies and continuously refined statistical algorithms for 
variant detection. Interest is that somatic variant detection goes across multiple fields of 
biology, e.g. developmental biology, tumour biology, neurobiology, toxicology and has even 
forensics applications. 
In the field of AD research, where the primary cause of sporadic AD is still unknown, the 
possibility of somatic mutations being pathogenic drivers is a long standing question [39, 40]. 
We foresee that continuous optimization of the methodologies will finally clarify the role of 
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somatic mutations in AD. Moreover, the methodologies illustrated in this chapter can be 
extended to other neurodegenerative diseases, in particular for those in which a template-seeded 
aggregation mechanism is involved, e.g. Parkinson disease [41, 42] and prion diseases. 
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Figure captions 
 
Figure 1. Different degrees of mosaicism and recommended workflows. 
 
Depending on the developmental timing of appearance of a mutation, it can appear in multiple 
cells (exemplified by the red patch in the “coarse-grain mosaicism”) or it can be private to a 
single cell (cell-private mutations are exemplified by the coloured dots in “fine-grain 
mosaicism”, where each dot is a different mutation). Depending on the prevalence of a mutation 
in a tissue, different sequencing approaches can be undertaken in the discovery phase. 
Methodologies for the validation phase are mainly dictated by the allelic frequency of the 
candidate variants. 
 
Figure 2. Principles of amplicon tagging. 
 
A low-frequency mutation (indicated by a star) is present only in a fraction of the reads 
(represented by a blue line ending with a circle) aligning on a genomic target of interest. When 
no read tagging is used (e.g. after sequence-enrichment of sheared gDNA), the allelic frequency 
of a somatic mutation cannot be corrected for PCR duplication artefacts (a). When reads are 
tagged prior to PCR amplification, duplicates can be easily spotted and the allelic frequency of 
the mutation can be corrected (b, tags indicated by the coloured circles at the end of each read). 
Deduplication of PCR artefacts leads to correct assessment of the allelic frequency of somatic 
variant also in the case that the somatic variant is not present in the duplicated reads (c). 
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Figure 3. Tag-deduplication algorithm. 
 
The algorithm represented has been implemented in a software developed in the lab to process 
UMI-labelled reads. The green box represents different possible scenarios of duplicated UMIs 
and connected reads. After alignment to the genome, reads and their associated UMIs are 
analysed position-by-position. Reads are grouped based on their UMIs into UMI families (e.g. 
UMI1, UMI2, UMI3). Depending on the duplication levels and on the supporting nucleotides 
found for different duplicate molecules, a read is either retained (accept) or discarded (reject). 
In the example (green box) UMI1 is unique and thus retained; UMI2 is duplicated but all 
nucleotides are the same and thus UMI2 is retained; UMI3 is duplicated and the most 
represented nucleotide is less than four-fold more abundant than the second, thus UMI3 is 
rejected. 
 
Figure 4. Titration of digital droplet PCR assay for a candidate variant. 
 
A ddPCR assay for a candidate variant is first tested for sensitivity by running appropriate 
negative and positive controls. Negative controls include a non-template control (NTC) sample 
and a wild type DNA sample, to check background probe fluorescence and non-specific 
hybridization, respectively. As positive controls we used a series of wild type DNA samples 
containing a spiked-in gBLOCK construct containing the candidate variant. We spiked in 3000, 
600, 120, 24 and 4.8 molecules of mutant gBLOCK construct per reaction, which corresponds 
to 10%, 2%, 0.4%, 0.08% and 0.016% of the number of alleles present in the template DNA in 
each reaction (100 ng of DNA, ~30,000 haploid genome copies). Data were analysed with 
BioRad QuantaSoft, and we report the calculated number of copies per μL of mutant (a) and 
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wild type allele (b); error bars are the 95% Poisson confidence intervals. The red line highlights 
the lowest sensitivity attainable, i.e. the upper boundary of the mutant allele count in the wild 
type sample. Hence, for this specific assay a variant can be called if its lower Poisson confidence 
interval is above 0.42 copies/μL. 
 
Table captions 
 
Table. Bioinformatics analysis software for DNA sequencing and variant calling analysis. 
 
In the table we provide a description and links for software mentioned in the methodologies, 
along with similar software that can be used for DNA sequencing analysis and somatic variant 
discovery. Links are updated and valid as of December 2016. 
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Table 
 
Name Purpose Link 
BWA 
alignment of raw reads to reference 
genome 
bio-bwa.sourceforge.net/ 
SAMtools 
handling of aligned reads, pileup of 
aligned reads 
samtools.sourceforge.net/ 
GATK 
handling of aligned reads, error 
correction, variant calling 
https://software.broadinstitute.o
rg/gatk/ 
VarScan variant calling 
http://dkoboldt.github.io/varsca
n/ 
SNVer variant calling snver.sourceforge.net/ 
LoFreq variant calling http://csb5.github.io/lofreq/ 
UMI-tools handling of unique molecular identifiers 
https://github.com/CGATOxfor
d/UMI-tools 
SnpEff variant annotation snpeff.sourceforge.net/ 
Annovar variant annotation 
www.openbioinformatics.org/a
nnovar/ 
Monovar 
Variant calling in single cell sequencing 
data 
https://bitbucket.org/hamimzafa
r/monovar 
Single Cell 
Genotyper 
Variant calling in single cell sequencing 
data 
https://bitbucket.org/aroth85/sc
g/wiki/Home 
R statistical analysis http://www.r-project.org/ 
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